Current Respiratory Care Reports

, Volume 3, Issue 1, pp 19–25 | Cite as

Immunotherapy for non-small-cell lung cancer: current approaches

  • Elisabeth Quoix
  • Jean Marc Limacher
Lung Cancer (C Mascaux, Section Editor)


Lung cancer has long been regarded as a poor candidate for immunotherapy, because it has a relatively low content of tumor-infiltrating lymphocytes compared with, for example, melanoma. However, new developments in immunotherapy are about to change this situation. Therapeutic vaccines are different from the well-known prophylactic vaccines, in that they are designed to treat patients already suffering from a disease instead of preventing the disease in healthy individuals. Several therapeutic vaccines are in late-stage clinical development for non-small-cell lung cancer (NSCLC). These vaccines use different approaches, including peptides, cell lines or viral vectors, and are used in different settings within the pathology. Some are given as monotherapy, whereas others are combined with traditional therapy for this indication. More recently developed, and very promising, are the checkpoint-blocking antibodies. It is likely that in the future several approaches, including immunotherapy products, will be combined in the evolving standard of care for lung cancer. This review gives a summary of the candidate immunotherapy products currently in late-stage clinical development for NSCLC.


Cancer vaccine Immunotherapy Lung cancer NSCLC Cancer Respiratory care 


Compliance with Ethics Guidelines

Conflicts of Interest

Jean-Marc Limacher is a permanent employee of Transgene. Elisabeth Quoix is the Principal Investigator of the trials of Transgene vaccine for lung cancer and have had some advisory activities related to Transgene. There is no monetary transaction regarding the article.

Human and Animal Rights and Informed Consent

The paper contains result of clinical studies (those with TG4010) for which Dr. Elisabeth Quoix, M.D. has been an investigator and Dr. Jean-Marc Limacher, M.D. as the medical lead from the industrial side. The studies were performed after approval by the appropriate Institutional Review Boards.


  1. 1.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.PubMedCrossRefGoogle Scholar
  5. 5.
    Gerard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol Oncol. 2009;3(5–6):409–24. doi: 10.1016/j.molonc.2009.09.001.PubMedCrossRefGoogle Scholar
  6. 6.
    O’Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol. 2005;23(35):9022–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23(27):6674–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Butts C, Socinski M, Mitchell P, Thatcher N, Havel L, Krzakowski M., et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol. 2013;31, 2013 (suppl; abstr 7500).Google Scholar
  9. 9.
    Merck Serono Announces Decision to Continue the Development of Tecemotide in Stage III Non-Small Cell Lung Cancer. 2013.Google Scholar
  10. 10.
    Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31(19):2396–403. doi: 10.1200/JCO.2012.43.7103.PubMedCrossRefGoogle Scholar
  11. 11.
    Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer. 2009;10(5):371–4. doi: 10.3816/CLC.2009.n.052.PubMedCrossRefGoogle Scholar
  12. 12.
    Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008;26(27):4418–25. doi: 10.1200/JCO.2008.16.6462.PubMedCrossRefGoogle Scholar
  13. 13.
    Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, Nyakas M, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011;17(21):6847–57. doi: 10.1158/078-0432.CCR-11-1385.PubMedCrossRefGoogle Scholar
  14. 14.
    Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 2009;16(8):620–4. doi: 10.1038/cgt.2009.15. Epub Mar 13.PubMedCrossRefGoogle Scholar
  15. 15.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Giaccone G, Bazhenova L, Nemunaitis J. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC). The European Cancer Congress. 2013;7(5):159–63.Google Scholar
  17. 17.
    D’Angelo S, Park B, Krug L. Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations. J Clin Oncol. 2011;29(20):2787–94.CrossRefGoogle Scholar
  18. 18.
    Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008;3(7):735–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. The Lancet Oncology. 2011;12(12):1125–33. doi: 10.1016/S1470-2045(11)70259-5.PubMedCrossRefGoogle Scholar
  20. 20.
    Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). J Clin Oncol. 2011;29(31):4129–36. doi: 10.1200/JCO.2010.34.4127.PubMedCrossRefGoogle Scholar
  21. 21.
    Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol. 2013;24(11):2875–80. doi: 10.1093/annonc/mdt371. Epub 2013 Sep 19.PubMedCrossRefGoogle Scholar
  22. 22.
    Agennix Reports Results of FORTIS-M Phase III Trial with Talactoferrin Alfa in Non-small Cell Lung Cancer. 2012.Google Scholar
  23. 23.
    Zielinski C, Knapp S, Mascaux C, Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol. 2013;24(5):1170–9. doi: 10.093/annonc/mds647.PubMedCrossRefGoogle Scholar
  24. 24.
    Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046–54. doi: 10.1200/JCO.2011.38.4032.PubMedCrossRefGoogle Scholar
  25. 25.
    Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J Thorac Oncol. 2013;8(5):587–98. doi: 10.1097/JTO.0b013e318286cf88.PubMedGoogle Scholar
  26. 26.
    Garon E, Balmanoukian A, Hamid O. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2013;8, Supplement 2.Google Scholar
  27. 27.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi: 10.1056/NEJMoa1200690.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Hodi F, Topalian S, Brahmer J. Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538) The European Cancer Congress. 2013.Google Scholar
  29. 29.
    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65. doi: 10.1056/NEJMoa1200694.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Soria J, Cruz C, Bahleda R. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1) The European Cancer Congress. 2013.Google Scholar
  31. 31.
    Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(1):20–30. doi: 10.1093/annonc/mds590.PubMedCrossRefGoogle Scholar
  32. 32.
    Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94. doi: 10.1056/NEJMoa1214886.PubMedCrossRefGoogle Scholar
  33. 33.
    Azzoli CG, Temin S, Aliff T, Baker Jr S, Brahmer J, Johnson DH, et al. Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol. 2011;29(28):3825–31. doi: 10.1200/JCO.2010.34.774.PubMedCrossRefGoogle Scholar
  34. 34.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079–88. doi: 10.1016/S0140-6736(11)60780-0.Google Scholar
  36. 36.
    Lilenbaum R, Villaflor VM, Langer C, O’Byrne K, O’Brien M, Ross HJ, et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009;4(7):869–74. doi: 10.1097/JTO.0b013e3181a9a020.PubMedCrossRefGoogle Scholar
  37. 37.
    Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013;31(19):2388–95. doi: 10.1200/JCO.2012.44.3762.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of PulmonologyUniversity HospitalStrasbourgFrance
  2. 2.Transgene SA, Medical AffairsIllkirchFrance

Personalised recommendations